These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 12494208)

  • 1. [Clinical assessment of prolonged therapy of patients with hypertension and diabetes with imidazoline receptor agonist moxonidine].
    Trusov VV; Aksenov KV; Filimonov MA
    Kardiologiia; 2002; 42(2):50-3. PubMed ID: 12494208
    [No Abstract]   [Full Text] [Related]  

  • 2. Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: a sequential, randomized, double-blind clinical trial.
    Derosa G; Cicero AF; D'Angelo A; Fogari E; Salvadeo S; Gravina A; Ferrari I; Fassi R; Fogari R
    Clin Ther; 2007 Apr; 29(4):602-10. PubMed ID: 17617283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective stimulation of I1-imidazoline receptors as a novel mechanism for antihypertensive action. Focus on moxonidine.
    Papp JG; Ollivier JP
    J Cardiovasc Pharmacol; 1994; 24 Suppl 1():v-vi. PubMed ID: 7533220
    [No Abstract]   [Full Text] [Related]  

  • 4. [Long-term antihypertensive therapy with moxonidine (cynt) in patients with insulin-independent diabetes mellitus].
    Lazebnik LB; Malichenko SB; Serebrov AN
    Ter Arkh; 1997; 69(6):59-64. PubMed ID: 9297279
    [No Abstract]   [Full Text] [Related]  

  • 5. Effective antihypertensive therapy: blood pressure control with moxonidine.
    Prichard BN; Graham BR
    J Cardiovasc Pharmacol; 1996; 27 Suppl 3():S38-48. PubMed ID: 8872298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective imidazoline receptor agonists for metabolic syndrome.
    Krentz AJ; Evans AJ
    Lancet; 1998 Jan; 351(9097):152-3. PubMed ID: 9449863
    [No Abstract]   [Full Text] [Related]  

  • 7. Imidazoline receptor agonist drugs for treatment of systemic hypertension and congestive heart failure.
    Palkhiwala SA; Yu A; Frishman WH
    Heart Dis; 2000; 2(1):83-92. PubMed ID: 11728244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy of moxonidine, an imidazoline receptor agonist, in patients with essential hypertension].
    Baliakina EV; Patrusheva IF; Rynskova EE; Iurenev AP
    Ter Arkh; 1998; 70(1):15-9. PubMed ID: 9532644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacology of moxonidine: an I1-imidazoline receptor agonist.
    Ernsberger P
    J Cardiovasc Pharmacol; 2000; 35(7 Suppl 4):S27-41. PubMed ID: 11346217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. I1 agents: a new approach to the treatment of hypertension.
    Dubar M; Pillion G
    Ann N Y Acad Sci; 1995 Jul; 763():642-58. PubMed ID: 7677384
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment of postmenopausal hypertension with moxonidine, a selective imidazoline receptor agonist.
    Kaaja R; Manhem K; Tuomilehto J
    Int J Clin Pract Suppl; 2004 Mar; (139):26-32. PubMed ID: 15117110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective imidazoline agonist moxonidine plus the ACE inhibitor ramipril in hypertensive patients with impaired insulin sensitivity: partners in a successful MARRIAGE?
    Rayner B
    Curr Med Res Opin; 2004 Mar; 20(3):359-67. PubMed ID: 15025845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The significance of the sympathetic nervous system during therapy for hypertension and related pathologies. Imidazoline-I1-receptor agonists. 17th Scientific Meeting of the International Society of Hypertension. Amsterdam, June 7, 1998].
    Dtsch Med Wochenschr; 1998 Aug; 123(33 Suppl):1-4. PubMed ID: 9739350
    [No Abstract]   [Full Text] [Related]  

  • 14. [Effect of the imidazoline receptor agonist moxonidine on hemodynamics, coronary circulation, metabolic ischemia markers and the neurohumoral system in patients with essential hypertension. Effects of moxonidine on coronary circulation].
    Mitrovic V; Hamel M; Miric M; Thormann J; Hamm C
    Z Kardiol; 2001 Dec; 90(12):953-63. PubMed ID: 11826837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective imidazoline agonist moxonidine in obese hypertensive patients.
    Sanjuliani AF; de Abreu VG; Francischetti EA
    Int J Clin Pract; 2006 May; 60(5):621-9. PubMed ID: 16700870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Moxonidine: a new antiadrenergic antihypertensive agent.
    Prichard BN; Graham BR; Owens CW
    J Hypertens Suppl; 1999 Aug; 17(3):S41-54. PubMed ID: 10489098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacology and clinical use of moxonidine, a new centrally acting sympatholytic antihypertensive agent.
    Prichard BN; Owens CW; Graham BR
    J Hum Hypertens; 1997 Aug; 11 Suppl 1():S29-45. PubMed ID: 9321737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Agonists of the imidazoline receptors].
    Ol'binskaia LI; Bochenkov IuV
    Eksp Klin Farmakol; 1999; 62(2):68-72. PubMed ID: 10340136
    [No Abstract]   [Full Text] [Related]  

  • 19. [New trends in the treatment of arterial hypertension: identification of the I1 receptor and the pharmacology of imidazoline].
    Pavlović P
    Vojnosanit Pregl; 1998; 55(3):305-10. PubMed ID: 9720446
    [No Abstract]   [Full Text] [Related]  

  • 20. [Imidazoline receptor agonists in the practical treatment of hypertension].
    Ol'binskaia LI; Bochenkov IuV; Alekseeva IL
    Ter Arkh; 1998; 70(2):86-8. PubMed ID: 9551585
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.